about
Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expressionRobust 8-color flow cytometry panel reveals enhanced effector function of NKG2C+ CD57+ FcεRγ- NK cells in CMV seropositive human blood donors.Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function.Karanjin interferes with ABCB1, ABCC1, and ABCG2.Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3.Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell PlatformThe tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cellsSuper-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-TROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor modelsUpregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
P50
Q35317533-EBC1B0D7-9DDB-48B6-B60D-E2915491C9B1Q36264473-4DB3D2DD-0C36-4829-9E8B-4A237664CC25Q38429183-933BBF00-7E79-43E2-94E5-433215E415D8Q39003846-AC990803-628D-498B-96FC-DA9BEBC7E0D2Q39003849-97067C89-9B70-4A42-8C31-DF05258E72DFQ42215521-5373CD64-8A32-4D5B-B3E1-31126C932AA8Q50910933-B84EFB49-FA83-4143-AEBC-D9435ACFF2B7Q52588130-D4F1866D-A711-420E-BF97-33EE352AD582Q52689076-92CA8AEA-1077-4D25-AE2C-2FA34A90BD72Q54119583-801395D7-693B-405E-9C9C-7519A2B41DB2Q90678696-E9ABE16C-6368-4C61-ABE4-2D931DB07E80Q91593777-C47B89EE-F124-44D2-AB7C-9650A17035D8Q91968022-2192A534-657E-4707-8245-BBA0E4F7D2A4Q92636828-9223AD4C-8BBE-4A59-B94B-0B2A62346F45Q94461793-617A085B-DFF4-45D9-9148-65087129FD82
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Nerreter
@ast
Thomas Nerreter
@en
Thomas Nerreter
@es
Thomas Nerreter
@nl
Thomas Nerreter
@sl
type
label
Thomas Nerreter
@ast
Thomas Nerreter
@en
Thomas Nerreter
@es
Thomas Nerreter
@nl
Thomas Nerreter
@sl
prefLabel
Thomas Nerreter
@ast
Thomas Nerreter
@en
Thomas Nerreter
@es
Thomas Nerreter
@nl
Thomas Nerreter
@sl
P214
P106
P21
P214
P31
P496
0000-0002-0493-1369
P735
P7859
viaf-309642035